-
Start Preamble
AGENCY:
Department of Veterans Affairs.
ACTION:
Notice.
SUMMARY:
This Department of Veterans Affairs (VA) Notice updates the information on Tier 1 medications.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Joseph Duran, Office of Community Care (10D), Veterans Health Administration (VHA), Department of Veterans Affairs, Ptarmigan at Cherry Creek, Denver, CO 80209; Joseph.Duran2@va.gov; telephone: (303) 370-1637 (this is not a toll-free number).
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Section 17.110 of Title 38 CFR governs copayments for medications that VA provides to Veterans. Section 17.110 provides the methodologies for establishing the copayment amount for each 30-day or less supply of medication provided by VA on an outpatient basis (other than medication administered during treatment).
Tier 1 medication means a multi-source medication that has been identified using the process described in paragraph (b)(2) of this section. Not less than once per year, VA will identify a subset of multi-source medications as Tier 1 medications. Only medications that meet all of the criteria in 38 CFR 17.110(b)(2)(i), (ii), and (iii) will be Start Printed Page 11455eligible to be considered Tier 1 medications; and only those medications that meet all of the criteria in paragraph (b)(2)(i) of this section will be assessed using the criteria in paragraphs (b)(2)(ii) and (iii).
Based on the methodologies set forth in § 17.110, this Notice updates the list of Tier 1 medications for Calendar Year 2020. The Tier 1 medication list is posted on VA's Community Care website at: https://www.va.gov/COMMUNITYCARE/revenue_ops/copays.asp under the heading “Tier 1 Copay Medication List.”
The following table is the Tier 1 Copay Medication List that is effective January 1, 2020 and will remain in effect until December 31, 2020.
Condition VA product name Arthritis and Pain Aspirin Buffered Tablet, Aspirin Chewable Tablet, Aspirin Enteric Coated Tablet, Allopurinol Tablet, Celecoxib Capsule, Diclofenac Tablet, Ibuprofen Tablet, Meloxicam Tablet, Naproxen Tablet. Blood Thinners and Platelet Inhibitors Clopidogrel Bisulfate Tablet, Warfarin Sodium Tablet. Bone Health Alendronate Tablet. Cholesterol Atorvastatin Tablet, Gemfibrozil Tablet, Lovastatin Tablet, Pravastatin Tablet, Rosuvastatin Calcium Tablet, Simvastatin Tablet. Dementia Donepezil Tablet. Diabetes Glimepiride Tablet, Glipizide Tablet, Metformin Hydrochloride (HCL) Tablet, Metformin HCL 24-hour Sustained Action (SA) Tablet, Pioglitazone HCL Tablet. Dizziness (Vertigo) Meclizine HCL Tablet, Meclizine HCL Chewable Tablet. Electrolyte Supplement Potassium SA Tablet, Potassium SA Dispersible Tablet. Gastrointestinal Health Omeprazole Enteric Coated (EC) Capsule, Pantoprazole Sodium EC Capsule, Ranitidine Tablet. Glaucoma and Eye Care Diclofenac 0.1% Solution, Dorzolamide 2%/Timolol 0.5% Solution, Latanoprost 0.005% Solution, PEG-400 0.4%/Propylene Glycol 0.3% Solution. Heart Health and Blood Pressure Amlodipine Tablet, Amiodarone HCL Tablet, Aspirin (see Arthritis and Pain), Atenolol Tablet, Benazepril Tablet, Carvedilol Tablet, Chlorthalidone Tablet, Clonidine Tablet, Diltiazem 24-hour Capsule, Diltiazem HCL Tablet, Enalapril Maleate Tablet, Furosemide Tablet, Hydrochlorothiazide Capsule/Tablet, Hydrochlorothiazide/Lisinopril Tablet, Hydrochlorothiazide/Losartan Tablet, Hydrochlorothiazide/Triamterene Capsule/Tablet, Isosorbide Mononitrate SA Tablet, Lisinopril Tablet, Losartan Tablet, Metoprolol Succinate SA Tablet, Metoprolol Tartrate Tablet, Nifedipine SA Tablet, Nitroglycerin Sublingual Tablet, Prazosin HCL Capsule, Propranolol HCL Tablet, Spironolactone Tablet, Verapamil HCL Tablet, Verapamil HCL SA Tablet. Mental Health Amitriptyline HCL Tablet, Bupropion HCL Tablet, Bupropion HCL SA (12HR-SR) Tablet, Bupropion HCL SA (24HR-XL) Tablet, Citalopram Hydrobromide Tablet, Duloxetine HCL EC Capsule, Escitalopram Oxalate Tablet, Fluoxetine Capsule/Tablet, Lithium Carbonate Capsule/Tablet, Mirtazapine Tablet, Paroxetine HCL Tablet, Sertraline HCL Tablet, Trazodone Tablet. Respiratory Condition Montelukast NA Tablet. Seizures Gabapentin Capsule/Tablet, Lamotrigine Tablet, Topiramate Tablet. Thyroid Conditions Levothyroxine Sodium Tablet. Urologic (Bladder and Prostate) Health Alfuzosin HCL SA Tablet, Doxazosin Mesylate Tablet, Finasteride Tablet, Sildenafil Tablet, Tamsulosin HCL Capsule, Terazosin HCL Capsule. Signing Authority
The Secretary of Veterans Affairs, or designee, approved this document and authorized the undersigned to sign and submit the document to the Office of the Federal Register for publication electronically as an official document of the Department of Veterans Affairs. Pamela Powers, Chief of Staff, Department of Veterans Affairs, approved this document on February 19, 2020, for publication.
Start SignatureLuvenia Potts,
Regulation Development Coordinator, Office of Regulation Policy & Management, Office of the Secretary, Department of Veterans Affairs.
[FR Doc. 2020-03834 Filed 2-26-20; 8:45 am]
BILLING CODE 8320-01-P
Document Information
- Published:
- 02/27/2020
- Department:
- Veterans Affairs Department
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2020-03834
- Pages:
- 11454-11455 (2 pages)
- PDF File:
- 2020-03834.pdf
- Supporting Documents:
- » High Risk List Action Plan, Managing Risks, and Improving Health Care; FR Doc. #2020-27939
- » Rescission of Record of Decision; FR Doc No: 2020-22543
- » Meetings: Advisory Committee on Cemeteries and Memorials; FR Doc No: 2020-22340
- » Meetings: Veterans and Community Oversight and Engagement Board; FR Doc No: 2020-16224
- » Update to Access Standards Drive Time Calculations; FR Doc No: 2020-14341;
- » Meetings: Rehabilitation Research and Development Service Scientific Merit Review Board; FR Doc. #2020-12485
- » Meetings: Advisory Committee on Education; FR Doc No: 2020-12409
- » Meetings: Cooperative Studies Scientific Evaluation Committee; FR Doc No: 2020-12248
- » Meetings: Advisory Committee on the Readjustment of Veterans; FR Doc. #2020-10591
- » Meetings: National Research Advisory Council; FR Doc. #2020-10522